v3.23.2
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue $ 0 $ 8 $ 5 $ 16
Operating expenses:        
Research and development 1,709 1,351 2,771 2,968
General and administrative 9,107 4,302 15,352 10,703
Depreciation and amortization 92 71 176 126
Total operating expenses 10,908 5,724 18,299 13,797
Loss from operations (10,908) (5,716) (18,294) (13,781)
Other income (expense):        
Interest income, net 3 0 7 0
Other income (expense), net: (225) 0 (225) 0
Loss before income taxes (11,130) (5,716) (18,512) (13,781)
Income taxes (benefit) 0 0 0 0
Net loss (11,130) (5,716) (18,512) (13,781)
Non-controlling interest 37 (43) 87 59
Net loss attributable to BioSig Technologies, Inc. (11,093) (5,759) (18,425) (13,722)
Preferred stock dividend (3) (3) (5) (5)
Preferred stock deemed dividend 0 (108) 0 (108)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS $ (11,096) $ (5,870) $ (18,430) $ (13,835)
Net loss per common share, basic and diluted (in Dollars per share) $ (0.16) $ (0.15) $ (0.28) $ (0.36)
Weighted average number of common shares outstanding, basic and diluted (in Shares) 70,281,555 39,823,034 65,878,496 37,920,734
Service [Member]        
Revenue $ 0 $ 8 $ 5 $ 16

Source